Depatuxizumab mafodotin
- Generic Name
- Depatuxizumab mafodotin
- Drug Type
- Biotech
- CAS Number
- 1585973-65-4
- Unique Ingredient Identifier
- F3R7A4P04N
- Background
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
- Indication
No approved indication.
A Study of ABT-414 in Subjects With Solid Tumors
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 57
- Registration Number
- NCT01741727
- Locations
- 🇺🇸
Site Reference ID/Investigator# 117516, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 90333, Scottsdale, Arizona, United States
🇺🇸Site Reference ID/Investigator# 83156, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath